|

Personalized Neoantigen DNA vaccine Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 2

Top Sponsors

  • Washington University School of Medicine2

Indications

  • Cancer2
  • Unmethylated Glioblastoma1
  • Pediatric Recurrent Central Nervous System Tumors1

St Louis, Missouri2 trials

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine

Phase 1
Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors

Washington University School of Medicine

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.